000			04210nam a22004335i 4500
999			_c381858 _d381858 _x1
001			381858
003			ES-MaUEC
005			20230102121935.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			220903s2022 si | s |||| 0|eng d
020			_a9789811672002
024	7		_a10.1007/978-981-16-7200-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC927 _b2022 EB
245	0	0	_aHandbook of Biologics for Rheumatological Disorders _cedited by Neeraj Jain, Lalit Duggal
250			_aFirst edition 2022
264		1	_aSingapore _bSpringer Singapore _c2022
300			_a1 recurso en línea (X, 288 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aHistory of Biologics -- Biologics in Rheumatoid Arthritis -- Biologics in Spondylarthritis -- Biologics in Psoriatic Arthritis -- Biologics in Gout -- Biologics in Lupus -- Biologics in Sjogren's Syndrome -- Biologics in Systemic Sclerosis -- Biologics in Inflammatory Myopathies -- Biologics in ANCA Associated Vasculitis -- Biologics inBehcet's Syndrome -- Biologicsin Takayasu's Arteritis -- Biologics in Interstitial lung disease in Rheumatological conditions -- Biologics in Osteoporosis -- Biologics in Osteoarthritis -- Biologics in JIA -- Biologics in Paediatric CTD -- JAK inhibitors in Rheumatology -- Biologics in Rheumatic disease with Infections -- Biologics in Rheumatological conditions with Malignancy -- Biologics in Uveitis -- Biologics in Sarcoidosis -- Biologics in IgG4-RD -- Biosimilar in Rheumatology -- Off label use of Biologics in Rheumatological disorders -- Biologics & Ethical issues in Rheumatology -- Patient consent for use of biologics.
520			_aBiologics have revolutionized the treatment of autoimmune diseases due to their efficacy, speed of onset, and tolerability. The development of new agents and expanded use of existing agents continues to be a highly active area of investigation among rheumatic diseases, with a multitude of innovative therapeutic strategies in various stages of development. Although the story of treatments continues rapidly, therapeutic research in some conditions is hindered by the rarity of the disease, variation in phenotype, and concerns about toxicity. This fast-paced development of therapeutics,necessitates immediate evaluation of individual biologic agents and their best use in the new treatment regimens. This book provides an inclusive approach with the existing evidence concerning effectiveness and implications on the usage of biologics in treating various rheumatologic disorders. It also covers the evidence behind the rational use of these agents in varied autoimmune diseases. This manual also offers a complete overview of the existing & futuristic biologic treatments, and draws recommendations on how to standardize the most suitable regimen for a specific patient in the context of current guidelines. The handbook of Biologics in Rheumatology serves as a present and concise compendium to the modern therapeutic developments in the field. This book is likely to benefit clinicians, residents, fellow and other healthcare workers dealing with rheumatological disorders, and also hard-core Rheumatologists, who are looking for a quick recap of Biologics of their interest.
988			_aSpringer_Medicine_2022
650		7	_2embne _9141883 _aReumatología
700	1		_aJain, Neeraj _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aDuggal, Lalit _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9789811671999
776	0	8	_iPrinted edition: _z9789811672019
776	0	8	_iPrinted edition: _z9789811672026
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-16-7200-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eIG _zSI